The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. "Postpartum depression is a serious and potentially li

Medovate announced its SAFIRA®  has received an Innovative Technology contract from Vizient, Inc. the US’s largest member-driven health care performance improvement company. The contract has been awarded based on the recommendation of SAFIRA® by hospital experts who serve on one of Vizient’s member-led, hospital and healthcare councils.  SAFIRA® was highlighted for its unique qualities, that potentially bring improvement to the healthcare industry.

Patients with serious illnesses continue to receive care without leaving home, thanks to a partnership between Tampa General Hospital (TGH) and Signallamp Health Inc., a leading chronic care management company based in Pennsylvania. More than 1,000 Tampa General patients currently are linked to advanced monitoring systems that communicate with their health care providers, reducing the number of visits to a doctor's office or hospital. "It's cost-effective, eff

Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (HHS), to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter (OTC) and point-of-care (POC) use. Cue’s test would detec

The cardiovascular combination developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer has been included in the World Health Organization (WHO) List of Essential Medicines1. This cardiovascular combination contains three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been shown to be effective in preventing cardiovascular problems after a heart attack, reducing death from cardiova

In the face of the ongoing supply issues affecting Intra-Abdominal Pressure (IAP) transducer kits, Sentinel Medical Technologies is stepping up to ensure that patient care remains uncompromised. The company's FDA-cleared product, TraumaGuard, is now readily available to fill the gap left by the shortage of CR BARD or Centurion IAP kits. IAP monitoring is a critical component of patient care in OR and ICU settings. It serves as a crucial guide for medical teams in assessing

Marathon Health, a leading provider of direct primary care for employers, today announced the acquisition of Cerner Workforce Health Solutions (WHS), a group of dedicated onsite and near-site health clinics. The acquisition will expand Marathon’s footprint, accelerating the reach of its unique population health model to more employers, locations and members. “Marathon Health is singularly dedicated to helping employers control healthcare costs by transforming healthcare

AmeriPro Health, a leading provider of patient logistics and last-mile healthcare delivery services, has acquired American Medical Response, Inc.'s (AMR) operations in Lexington and Louisville, Kentucky, and New Albany, Indiana. As a result of the acquisition, AmeriPro Health now provides these three markets, which include UofL Health, University of Louisville Athletics and UK HealthCare, with its customizable suite of patient-centric 911, inter-fac

U.S. Physical Therapy, Inc., a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced an acquisition of a physical therapy practice with five clinics. USPH acquired a 70% equity interest in the practice for a purchase price of $2.1 million, with the current practice owners retaining a 30% equity interest. The business currently generates approximately $2.4 million in annual revenues. About U.S

Mainz Biomed NV  a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebone Laboratory has introduced ColoAlert®, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer - to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration m